安罗替尼的研究现状及其应用于晚期口腔鳞状细胞癌的治疗前景  

The current states of anlotinib and its prospect in advanced oral squamous cell carcinoma

作　　者：楚晨 孙艳[1,2] 尚伟[2,3] 张晓春[4] 葛胜优 Chu Chen;Sun Yan;Shang Wei;Zhang Xiaochun;Ge Shengyou(Department of Stomatology,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;School of Stomatology of Qingdao University,Qingdao 266000,China;Department of Oral and Maxillofacial Surgery,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Precision Medicine Center of Oncology,The Affiliated Hospital of Qingdao University,Qingdao 266000,China)

机构地区：[1]青岛大学附属医院口腔内科,266000 [2]青岛大学口腔医学院,266000 [3]青岛大学附属医院口腔颌面外科,266000 [4]青岛大学附属医院肿瘤精准医学中心,266000

出　　处：《中华口腔医学研究杂志（电子版）》2020年第5期325-329,共5页Chinese Journal of Stomatological Research(Electronic Edition)

摘　　要：晚期口腔鳞状细胞癌(OSCC)患者生存期短,预后较差。由于手术效果不佳、耐药性、不良反应等原因,亟需更安全有效的新型化疗药物以提高晚期OSCC患者生存质量。安罗替尼(anlotinib)是我国自主研发的一种口服多靶点小分子酪氨酸激酶抑制剂,能够与多种血管生成因子受体靶向结合,抑制肿瘤血管生成,干扰肿瘤细胞增殖等生物学行为,有望成为多种晚期恶性肿瘤治疗药物。本文对安罗替尼的作用机制、研究现状及其应用于晚期OSCC术后化疗的治疗前景等进行分析综述。Patients with advanced oral squamous cell carcinoma often show short survival time and poor prognosis.Because of the poor efficacy of surgery,drug resistance and adverse events etc.,the quality of life of these patients are required to improved by novel drugs with safety and efficacy.Anlotinib is a domestic small⁃molecule tyrosine kinase inhibitor,which has been presently regarded as a potential medicine for multiple advanced malignances.It targets multiple angiogenetic factor receptors to suppress the angiogenesis and inhibit partial functions of tumor cells.This review will focus on the mechanism,research status of anlotinib and its potential efficacy in advanced oral squamous cell carcinoma.

关 键 词：癌 鳞状细胞 血管内皮生长因子类 安罗替尼 血管生成 化疗 

分 类 号：R739.8[医药卫生—肿瘤]